Immune Subtyping Identifies a Subset of HR+HER2-early-stage Breast Cancer Patients with a Very High Likelihood of Response to Neoadjuvant Immunotherapy (IO): Results from 5 IO Arms of the I-SPY2 TRIAL Denise M. Wolf,Christina Yau,Lajos Pusztai, Rita Nanda,Jo Chien,Erica Stringer-Reasor,Rebecca Shatsky,Claudine Isaacs,MInetta Liu,Hyo Han,Hatem Soliman,Michael Campbell,Annuska Glas,Andrei Barcaru, Lorenza Mittempergher,Midas Kuilman,Lamorna Brown Swigart,Gillian Hirst,Hongmei Yu,Philip Beineke,Amrita Basu,Douglas Yee,W. Fraser Symmans,Angela DeMichele,Jane Perlmutter,Amy Delson,Laura Huppert,Hope Rugo,Amy Clark,Nola Hylton,Paula Pohlmann,Laura Esserman,Laura van 't VeerCANCER RESEARCH（2024）引用 0|浏览13暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
